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Abstract
Background: Some variables have been proposed as predictors of efficacy of OnabotulinumtoxinA in chronic migraine
patients, but data available are inconclusive. We aimed to analyse the influence of single nucleotide polymorphisms in
the response to OnabotulinumtoxinA.
Methods: We included 156 female patients treated with OnabotulinumtoxinA accordingly to PREEMPT paradigm in
three headache units. OnabotulinumtoxinA was offered to patients that had not responded to topiramate and at least
one other preventative. Age at first procedure was 43.7 ± 11.8 years (16–74). Patients with a reduction of at least 50% in
the number of migraine days after two OnabotulinumtoxinA procedures were considered as responders. We analysed
25 polymorphisms selected for their relevance regarding migraine pathophysiology and their association with migraine
according to previously published genome-wide association studies. Genotyping was performed using KASP probes and
a LightCycler-480 (Roche-Diagnostics). Allelic, genotypic frequencies and dominance/recesivity hypothesis of the allelic
variants were compared between responders and non-responders by Fisher’s exact test.
Results: Response to treatment with OnabotulinumtoxinA was achieved in 120 patients (76,9%). Two polymorphisms
showed differences: CALCA rs3781719, where allele C represents 26.9% in responders and 40.9% in non-responders
(p = 0.007, OR = 3.11 (1.33–7.26)); and TRPV1 rs222749, where allele A represents 4.17% in responders and 12.5% in
non-responders (p = 0.013, OR = 3.29 (1.28–8.43)). No significant differences in rest of polymorphisms or clinical or
demographic variables were found.
Conclusions: Polymorphic variations of CALCA and TRPV1 genes might play a role as prognostic markers of efficacy of
OnabotulinumtoxinA in chronic migraine female patients in our population.
Keywords: CALCA gene, Chronic migraine, OnabotulinumtoxinA, Single nucleotide polymorphisms, TRPV1 gene
Background
Chronic migraine (CM) is a debilitating neurological dis-
order which affects approximately 2–3% of adults and is
five times more frequent among female. The pathophy-
siology of migraine attacks is based on the activation of
the trigeminovascular system and the liberation of vaso-
active neuropeptides which cause meningeal inflammation
and produce pain, such as the calcitonin gene related pep-
tide (CGRP) [1].
OnabotulinumtoxinA (OnabotA) is considered a
safe and effective therapy to manage CM, as was
shown in the PREEMPT clinical program [2–5].
Also in a real-life clinical practice OnabotA pericra-
nial injections effectively reduced headache and mi-
graine days [5–11].
Molecular mechanism of action of OnabotA consists
on cleaving SNAP-25 and, so, impairing intracellular
vesicular fusion and down regulating release of pain
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related neuropeptides, such as glutamate, substance P or
CGRP [12, 13]. In addition, OnabotA blocks the trans-
location of membrane receptors to the surface of sensory
neurons, such as the Transient Receptor Potential Vanil-
loid 1 (TRPV1) [14]. Decreasing peripheral sensitization
by all these mechanisms, OnabotA would finally in-
directly inhibit central sensitization [15].
Genetics is considered a key factor for migraine sus-
ceptibility. Some genes have been postulated as respon-
sible for the appearance of migraine. These are related
to ion channel and neurotransmitter pathways (glutam-
ate, GABA, dopamine, serotonin) [16], vascular func-
tions (CGRP, MTHFR) [16, 17], hormonal mechanisms
[16] and nociceptive system (like receptors of the tran-
sient receptor potential family or TRP) [18].
Up to date, many predictors of response to OnabotA
in CM patients have been proposed. They have been
mainly related with the mechanism of action of
OnabotA (as plasma levels of CGRP) [19] and with
parameters that might imply a loss of possibility of
dechronification of migraine as age, time from onset of
migraine or chronic migraine [20], or structural or
functional changes in pain related brain structures [21].
Data regarding a possible influence of migraine charac-
teristics (strictly unilateral location, implosive pain, the
presence of cutaneous allodynia or pericranial tender-
ness) have shown inconclusive [22].
We aimed to analyse single nucleotide polymorphisms
(SNPs) previously related with a possible susceptibility
to migraine, and to determine their value as prognostic
markers of efficacy, in a population of CM patients
treated with OnabotA.
Methods
Patients and study design
A prospective, observational, multicentre study was
conducted in which demographic and clinical data, along
with biological samples, were collected from 156 female
patients affected by CM between January 2014 and
December 2015.
20 male patients were firstly included in the cohort
but not analysed as we found this number too low for
comparison.
The patients were recruited in the Headache Units of
three Tertiary Hospitals: Hospital Clínico Universitario
de Valladolid, Hospital Central de Asturias and
Hospital Universitario de La Princesa. All of them were
of Caucasian ethnicity and Spanish origin, and no siblings
were included.
Written informed consent was obtained from all the
patients to perform genetic analysis.
Scientific as well as ethical approvals were obtained
from the Clinical Research Ethics Committee (CEIC) of
East Valladolid Area (Hospital Clínico Universitario de
Valladolid) as well as CEIC of Hospital La Princesa, ac-
cording to the Declaration of Helsinki (1975). Patient
anonymity and adherence to Data Protection Laws were
maintained at all times.
CM was diagnosed accordingly to International Classi-
fication of Headache Disorders, III edition, beta version
[23]. All patients included were eligible for treatment
with OnabotA in accordance with the PREEMPT proto-
col. Exclusion criteria for the use of OnabotA were preg-
nancy, breastfeeding, and drug or alcohol abuse. We did
not exclude medication overuse and our patients were
allowed to continue with previous preventatives with no
dose increasing.
License of OnabotA in Spain indicates its use “for
patients who have not adequately responded or are
intolerant to prophylactic drugs for migraine”. Inclusion
criteria in our study considered patients previously
treated with topiramate (or another neuromodulator in
case of intolerance) and at least one other preventative
(among beta-blockers or calcium antagonists) with no
efficacy. Lack of response was evaluated after the admin-
istration of these drugs at adequate doses during at least
3 months, unless intolerance.
OnabotA was injected accordingly to PREEMPT
protocol. The patients used a diary in order to record
migraine and headache days and the days in which
symptomatic medications were used. We also gathered
time (years) from onset of migraines and time (months)
from onset of chronic migraine. Response to treatment
with OnabotA was evaluated 3 months after the second
procedure and was defined as a reduction of at least 50%
in the number of monthly migraine days.
We analysed 25 SNPs from each patient; they were
selected for their relevance regarding migraine patho-
physiology and their association with migraine accord-
ing to previously published genome-wide association
studies (GWAS). So, some polymorphisms were directly
related to an increasing in the occurrence of migraine
(MEF2D, MTHFR, MTDH, TRPV1 GABRQ, GABRE
and GABRA3, this latter only in the case of female
population), and others with processes that might be
part of it: SLC1A2 were linked to the tendency to
excessive use of symptomatic medication in migraine
patients, GRIK3 with schizophrenia, which shares with
migraine processes related to the glutamatergic system,
and SCN9A, P2RX7 and KCNS1 with increased pain
chronification [24–31].
Genes and SNPs studied as well as the change in DNA
sequence (NM or NC), changes caused to proteins (NP),
its OMIM reference number and the position of each
gene in each chromosome are shown in Table 1.
Considering that this was the first study addressing
the relationship between the variants and genes and
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OnabotA response, we estimated the sample size
using the most similar study from a similar popula-
tion [28]. We evaluated the highest possible variance
(0.164) and the smallest possible difference in the
proportions (0.15), with a type 1 error of 5% and a
statistical power of 90%, with a possible attrition rate
of 15%, with a minimum estimated sample size of
147 patients.
Sample collection and genotyping
Three mL of peripheral blood anticoagulated in EDTA-K3
were collected from each patient and from this was
extracted the genomic DNA using the commercial kit
“Ultra Clean® Blood DNA Isolation”, following the
manufacturer’s protocol. The DNA obtained was quan-
tified using the spectrophotometer NanoDrop ND1000
(Thermo Fisher Scientific, Inc.®) and genotyping was
then carried out with KASP probes (Kompetitive Allele
Specific PCR, KBioscience®) which are based on poly-
merase chain reaction (PCR) with the simultaneous use
of two specific forward primers, each one of which
differs in only one nucleotide so as to be able to recog-
nise the two possibilities of alleles which exist in a
point mutation or SNP.
The fluorescent emissions of the PCR product were
measured at 37 °C in a LightCycler 480® (Roche Diagnos-
tics). The absorbance measure determined the alleles (in
homo or heterozygosis) according to the fluorescence
emitted by the fluorophores FAM and/or HEX. The
homozygotes emitted the signal of only one fluorophore
and the heterozygotes of both.
Statistical analysis
Using the Fisher’s exact test, an assessment was made to
see if the genotypic frequencies of each variant fulfilled
the Hardy-Weinberg equilibrium.
Subgroups were established within the cohort of pa-
tients: responders and non-responders. We firstly ana-
lysed if clinical and demographic variables related with
the response to OnabotA. We also searched for any dif-
ferences between the groups in relation to any of the 25
SNPs for allelic, genotypic frequencies and dominance/
recesivity hypothesis of the allelic variants. For this pur-
pose, 3 × 2 contingency tables were used to analyse
genotypic distribution and 2 × 2 contingency tables for
the analysis of allele distribution and of allele domin-
ance/recesivity, using the Fisher’s exact test.
The statistical analysis was carried out using ver-
sion 20.0 of the IBM-SPSS programme for Windows.
Values for p of less than 0.05 were considered to be
statistically significant, taking into account the
Bonferroni correction.
In all cases where a significant association was found,
a binary logistic regression was performed, adjusting for
age, in order to determine the possible influence of this
variable in the signification found.
To estimate the risk derived from the significant
differences, the Odds Ratio (OR) statistical measure
was calculated with a 95% confidence interval. Thus,
several comparisons were made for those which
obtained a value of the odds ratio: for the allele of
greater risk versus the allele of less risk and for risk
according to three genetic models: dominant, codomi-
nant and recessive, using Bonferroni adjustment for
multiplicity correction.
Results
Among the 156 patients included in the study, 91
(58.3%) were included in Valladolid, 10 (6.4%) in
Madrid and 55 (35.3%) in Asturias. Age at inclusion
was 43.7 ± 11.8 years.
Response to treatment with OnabotA was achieved in
120 patients (76.9%).
None of the demographic variables considered predict
significantly response to OnabotA.
All of the variants analysed were found to be in
Hardy-Weinberg Equilibrium except one. This excep-
tion was SNP rs222749, located on the gene TRPV1
(p = 0.00006).
Results regarding relationship between SNPs and re-
sponse to OnabotA are shown in Appendices 1, 2.
Among the variables studied, after correction for
multiple comparisons, there were two which showed
significant differences between the groups of responders
and non-responders.
Significant differences in SNP rs3781719 of the gene
CALCA were found. Allele C represented 40.9% of
non-responders and only 26.9% of responders (Table 2).
For this SNP, the results of genotype determination in 7
samples were inconclusive, so the cohort consisted of
149 patients instead of 156.
Regarding the strength of association, the following
values of Odds Ratio were obtained with confidence
intervals of 95%: allele C related with a greater risk of
non-response than allele T: [OR = 1.88 (1.06–3.32)]
and, in relation to genetic models, the dominant
model had a value of OR = 3.11 (1.33–7.26); the co-
dominant model had a value of OR = 1.6 (0.85–3.00)
and the recessive model had a value of OR = 1.2
(0.31–4.71).
The SNP rs222749 located on the gene TRPV1 also
showed significant differences between the two groups.
Allele A represented 12.5% in non-responders and 4.17%
in the group of responders (Table 3).
Regarding the strength of association, the following
values of Odds Ratio were obtained with confidence
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intervals of 95%: allele A related with a greater risk
of non-response than allele G [OR = 3.29 (1.28–8.43)]
and, in relation to genetic models, the dominant
model had a value of OR = 2.47 (0.81–7.48); the co-
dominant model had a value of OR = 2.40 (0.80–7.24)
and the recessive model had a value of OR = 10.82
(1.09–107.45).
All the results were confirmed by age-adjusted logistic
regression.
None of the clinical and demographic variables con-
sidered in our population predicted OnabotA response.
Discussion
Efficacy of OnabotA in CM patients in our series is
comparable to recent “real-life” data [10].
There are lots of SNPs that have been associated with
migraine in GWAS [24–31], and have been validated
with other independent studies. These SNPs are located
in genes related to migraine pathophysiology. So occurs
with glutamate, the main excitatory neurotransmitter in
the central nervous system (CNS) whose levels have
been shown increased in the cerebrospinal fluid and
serum of migraineurs. Another example is Gamma-
Amino Butyric acid (GABA), the main inhibitory
neurotransmitter in the CNS. Also with CGRP, a
powerful vasodilator neuropeptide and mediator of
neurogenic inflammation. Or with the methylene-tetra-
hydrofolate reductase (MTHFR) system and the angio-
tensin converting enzyme, both related to vascular
disorders. Others genes considered are related with
voltage dependent channels involved in nociceptive
signalling, with neurotransmitters such as dopamine or
serotonin and with receptors of the transient receptor
potential family (TRP) which are expressed in the noci-
ceptive neurons of the trigeminal nerve and whose
activation leads to the release of CGRP [16, 18, 32, 33].
There are no many studies considering pharmacogen-
etics of migraine. Most of them have explored predictors
of response of migraine attacks to triptans. So, polymor-
phisms related to triptan metabolizing enzymes
(monoamine oxidase A, CYP3A4, CYP1A2 [34], COMT
[35]) to serotonin (5-HT1B) and dopamine (DRD2)
receptors [36] and to the serotonin transporter gene
SLC6A4 [37] have been explored as possible predictors
or response to triptans in episodic migraine patients.
Considering preventive therapies, certain mitochon-
drial DNA haplogroups showed influence in response to
riboflavin in migraine patients [38]. Nevertheless, to the
best of our knowledge, no previous study has addressed
the relationship between the variants and genes included
in this study and response to OnabotA.
The relationship between an SNP and a particular
phenotype is more consistent when sample size is
large, when the gene is located in a related area of
genetic linkage (for example in the case of migraine
in an area related to pain response) or if the re-
lationship has been demonstrated in animal models
[39]. Given the scarcity of individuals suffering from
CM who are resistant to preventive oral treatment
or OnabotA injection, and especially the low fre-
quency of some haplotypes, the sample size used in
this study might be considered as small. Hence, the
significant results should be considered with caution
even though the same level of significance might be
found in other similar groups involved in other inde-
pendent studies that might validate the findings. It is
also important that the subjects being compared
here belong to the same ethnic group. In our study,
all the patients were of Caucasian ethnicity and of
Spanish origin.
Furthermore, the SNPs variant should modify the
regulation of the gene (SNP promoter) or its primary
structure (SNP exon). Although certain genes can, by
themselves, be related to patients having a greater sus-
ceptibility to suffer migraine, it sometimes occurs that
they are reflecting what is happening in a neighbouring
gene, since many alleles segregate themselves in bloc
forming haplotypes within which are found several
genes. The protein related to such a gene must be impli-
cated in the pathogenesis of the illness. The genes being
studied must be selected according to the evidence that
there is a probability of association with the illness, on
the basis of previous studies which support the relation-
ship between those genes and the pathogenesis of the
illness (studies in animal models, in illnesses where there
Table 3 Association between response to OnabotA and SNP rs222749 in gene TRPV1
P value Odds ratio (95% CI)
POPULATION RESPONSE GENOTYPES MINOR
ALLELE
FREQUENCY
(%)
GENOTYPIC
FREQUENCY
ALLELE
FREQUENCY
ALLELE A
RECESIVITY
HYPOTHESIS
ALLELE A
DOMINANCE
HYPOTHESIS
Dominant
model
Codominant
model
Recessive
model
GG GA AA
n = 156 Responders (n = 120) 111 8 1 4,2 0,040 0,021 0,013 0,102 2,47
(0,81-7,48)
2,40
(0,80-7,24)
10,82
(1,09-107,45)
Non-responders
(n = 36)
30 3 3 12,5
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is a familial tendency, etc.) [40]. That was we have tried
to do in our design.
The definition of the phenotype of the illness and of
its development should be sufficiently homogeneous or
serious in patients to make comparison possible. In this
case, patients included were diagnosed of CM accor-
dingly to the ICHD-III beta [23] and resistance to pre-
vious oral preventatives was clearly defined.
As far as the handling of samples is concerned, it must
be meticulous, since a percentage of error in this type of
study on the scale of 1–3% has been described, leading
to the drawing of false conclusions [41]. To avoid errors
from the contamination of samples, sterility measures
should be maximised. Also, in the process of genotyping,
white control wells and empty control wells were used;
repeating the genetic analysis was considered when the
degree of allele discrimination was not clear, or not
including the results where they were inconclusive as
it happened with 7 samples regarding CALCA gen in
our study.
Migraine, as other pain disorders, is more prevalent
in females. Multiple phenotype differences between
male and female migraine have been described. Symp-
toms as allodynia, response to triptans or preventatives,
psychiatric comorbidities, and even brain structures or
functional connectivity showed sex differences in mi-
graine [42]. This heterogeneity provides us the oppor-
tunity to sub-classify our population and develop a
genetic analysis considering only the female sub-popu-
lation as we have done in this study.
All the variables considered were in Hardy-Weinberg
equilibrium except one which deviated from it with a
significance of p = 0.00006. The SNP in question was
rs222749, located on the TRPV1 gene. The lack of equi-
librium in the hardy-Weinberg law can be explained ei-
ther by the small sample size, in which there are very
infrequent haplotypes, or by the existence of selection
bias. The latter situation is produced when there is a
close relationship between the selection criterion, in our
case CM, and the SNP. The results relating to whether
this variant is a cause of CM are not completely conclu-
sive and so it may be argued that the disequilibrium is
due to a very low frequency of one of the alleles (only 4
homozygous patients in our population). However, al-
though there is no literature about the implication of
TRPV1 in chronic migraine, this gene has been widely
studied like an important molecular player in chronic
pain states, like chronic migraine [43].
The SNP rs3781719 c.-767 T > C of the CALCA gene
showed significant differences between the group of re-
sponders and the group of non-responders to OnabotA.
All of the analyses were statistically significant, particu-
larly the hypothesis of dominance of the allele C (p
= 0.007), whose presence, not only as homozygous but
also as heterozygous, impedes the response to OnabotA.
The CALCA gene encodes for the peptide CGRP,
whose involvement in migraine has been studied
widely [44]. CGRP levels have been proposed as a
marker of migraine, mainly of chronic migraine [45, 46].
When OnabotA is used in CM patients, a decreasing of
interictal levels of CGRP have been shown [47]. Finally,
the increased levels of CGRP have been proposed as
predictors of efficacy of OnabotA therapy in these
patients [19, 48].
Results of our study support the role of CGRP in the
therapeutic response of CM and its usefulness as a
biomarker or therapeutic target, especially taking into
account that the position c.-767 T > C of SNP rs3781719,
located in the promoter region 5-UTR, could alter the
expression of the gene. Our data suggest a possible
regulatory role of the response to OnabotA mediated by
the CALCA gene.
The SNP rs222749 located on the gene TRPV1
also showed significant differences between the two
groups. Allele A represents 4.17% of the responders,
while in the group of non-responders it is 12.5%.
This would support the hypothesis that OnabotA
interferes with the response mediated by the TRPV1
receptor [14], encoded by that gene, and as a result
impedes the release of neuropeptides implicated in
pain, such as CGRP or substance P. The reduction
of sensitivity to TRPV1 channels could be of in-
terest to explain the effect of OnabotA as migraine
preventative [49]. Thus, the patients with allele A
in homozygous state would be more susceptible to
the release of those neuropeptides.
In our study clinical and demographical variables con-
sidered did not correlate with response to OnabotA in
CM patients. The series which showed correlation of
time from onset of migraine and chronic migraine with
good outcome included a quite larger number of
patients than our study [20].
We did not consider if the presence of sympathetic or
parasympathetic symptoms correlated with the geno-
type or if other parameters influenced the response.
Future studies should explore this possible association
in detail.
Conclusions
In conclusion, in this study, and for the first time,
two genetic polymorphisms have been associated with
the response to therapy with OnabotA in Chronic
Migraine patients. These polymorphisms are situated
on the CALCA and TRPV1 genes. However, the role
of the SNPs identified has to be considered with
caution and the results have to be validated by other
independent studies.
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Appendix
Table 4 Response to OnabotA
No (n) Yes (n)
rs145837941 (CALCA)
AA 18 63
AG 0 0
GG 0 0
rs1800497 (DRD2)
AA 1 2
AG 7 25
GG 15 38
rs2201169 (GABRA3)
TT 28 80
TC 8 38
CC 0 2
rs1139916 (GABRE)
AA 6 10
CA 14 57
CC 16 53
rs6691840 (GRIK3)
AA 23 66
AC 13 43
CC 0 9
rs734784 (KCNS1)
GG 8 29
GA 14 56
AA 13 34
rs1050316 (MEF2D)
TT 16 51
TG 17 56
GG 3 13
rs121434294 (MTHFR)
CC 19 68
CT 0 0
TT 0 0
rs2230912 (P2RX7)
AA 27 85
AG 8 28
GG 1 3
rs7640543 (TGFBR2)
AA 4 11
AG 17 60
GG 15 49
rs222741 (TRPV1)
TT 18 64
TC 15 51
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Table 4 Response to OnabotA (Continued)
No (n) Yes (n)
CC 2 5
rs222749 (TRPV1)
AA 3 1
GA 3 8
GG 30 111
rs734312 (WFS1)
AA 12 34
AG 14 55
GG 9 31
rs3781719 (CALCA)
TT 9 63
TC 21 45
CC 3 9
rs4354668 (EAAT2)
GG 3 22
GT 16 54
TT 17 43
rs6627221 (GABRA3)
CC 1 3
CT 8 44
TT 27 73
rs3810651 (GABRQ)
TT 7 19
TA 17 55
AA 11 42
rs3813929_1732 (HTR2C)
TT 1 2
CT 15 35
CC 20 82
rs11172113 (LRP1)
CC 4 13
CT 18 49
TT 14 58
rs1835740 (MTDH)
GG 24 73
GA 10 43
AA 2 4
rs1718119 (P2RX7)
TT 3 17
TC 16 47
CC 17 55
rs6746030 (SCN9A)
GG 29 88
AG 6 30
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Table 4 Response to OnabotA (Continued)
No (n) Yes (n)
AA 1 1
rs10166942 (TRPM8)
TT 25 85
TC 9 32
CC 2 3
rs222747 (TRPV1)
GG 21 70
GC 12 43
CC 3 6
rs7217270 (TRPV3)
AA 9 21
AG 16 54
GG 11 45
Table 5 Response to OnabotA. Statistical analysis
FAMILY GENE SNP p
CHANGE ANALYSIS
BY PHENOTYPE
ALLELE
FREQUENCY
ALLELE VARIANT
RECESIVITY HYPOTHESIS
ALLELE VARIANT
DOMINANCE HYPOTHESIS
Genes related to
glutamate homeostasis
MEF2D rs1050316 G > T 0.907 0.729 0.836 0.665
LRP1 rs11172113 T > C 0.583 0.439 0.963 0.319
MTDH rs1835740 A > G 0.596 0.740 0.527 0.543
EAAT2 rs4354668 T > G 0.266 0.105 0.147 0.231
GRIK3 rs6691840 A > C 0.218 0.176 0.088 0.397
CGRP CALCA rs3781719 T > C 0.023 0.029 0.794 0.007
rs145837941 A > G – – – –
GABA
Receptor system
GABRE rs1139916 A > C 0.312 0.522 0.977 0.148
GABRQ rs3810651 A > T 0.824 0.532 0.619 0.604
GABRA3 rs6627221 T > C 0.271 0.190 0.977 0.074
rs2201169 T > C 0.381 0.195 0.436 0.205
Voltage dependent channels SCN9A rs6746030 G > A 0.400 0.603 0.367 0.419
KCNS1 rs734784 A > G 0.615 0.458 0.854 0.333
P2RX7 rs2230912 A > G 0.972 0.863 0.950 0.837
rs1718119 C > T 0.628 0.584 0.351 0.916
Dopamine receptor DRD2 rs1800497 C > T 0.775 0.699 0.773 0.569
Serotoninergic receptor HTR2C rs3813929 C > T 0.332 0.163 0.675 0.139
TRPfamily TRPV1 rs222749 G > A 0.040 0.021 0.013 0.102
rs222747 G > C 0.749 0.740 0.459 0.958
rs222741 C > T 0.922 0.777 0.843 0.698
TRPV3 rs7217270 A > G 0.553 0.275 0.446 0.317
TRPM8 rs10166942 T > C 0.656 0.655 0.361 0.873
Others WFS1 rs734312 G > A 0.767 0.655 0.498 0.989
TGFBR2 rs7640543 G > A 0.925 0.920 0.729 0.929
MTHFR rs121434294 C > T – – – –
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